Early Serum Markers for Immune Checkpoint Inhibitor Induced Hypophysitis in Melanoma Patients.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have shown promising anti-tumor activities and are widely used for the treatment of advanced cancers. However, they may lead to immune-related adverse events (irAEs) and some of them, such as hypophysitis, can be life-threatening. Here, early diagnosis is critical.

Methods

We retrospectively analyzed 40 melanoma patients who developed hypophysitis during ICI treatment with either ipilimumab and/or anti-PD1 therapy and compared them to 40 control patients who did not develop hypophysitis during the ICI treatment, matched for age, gender, type of immunotherapy, and stage. Clinical data and blood values such as LDH, CRP, TSH, T3, T4, and absolute immune cell counts were retrieved from the medical records. Patient characteristics, l

SUBMITTER: Mitri F 

PROVIDER: S-EPMC11010823 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature